47 filings
Page 2 of 3
8-K
tvexwhaguso 0a7cs
5 Sep 19
Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024
6:26am
8-K
aydyuda9x
3 Sep 19
Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024
5:02pm
8-K
8xfi6f q0
20 Aug 19
Regulation FD Disclosure
6:41am
8-K
a2rt6wv9c ytbu42q
13 Aug 19
Regulation FD Disclosure
6:30am
8-K
tmpf6sr
7 Aug 19
Aerie Pharmaceuticals Reports Second Quarter 2019
4:04pm
8-K
fihd3j1
23 Jul 19
Regulation FD Disclosure
6:32am
8-K
fycw 3cil93mdu74al2m
9 Jul 19
Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule
6:42am
8-K
rodqvn 58
13 Jun 19
Regulation FD Disclosure
6:31am
8-K
k7r 48w8cb
4 Jun 19
Regulation FD Disclosure
6:34am
8-K
njsu6x7l
23 May 19
Submission of Matters to a Vote of Security Holders
4:24pm
8-K
hc30rpv 7qp0j
14 May 19
Regulation FD Disclosure
6:32am
8-K
x5e6ytbum2lb6rgnu8r0
7 May 19
Aerie Pharmaceuticals Reports First Quarter 2019
4:17pm
8-K
dhl0mw
3 May 19
Aerie Pharmaceuticals Announces Additional Undrawn $100M
7:43am
8-K
jr210z
1 May 19
Regulation FD Disclosure
6:40am
8-K
d6h294c og919uu58f
25 Apr 19
Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application
6:42am
8-K
5uzvp5
8 Apr 19
Regulation FD Disclosure
6:32am
8-K
q7pmn7 m30ip
21 Mar 19
Regulation FD Disclosure
6:35am
8-K
gzpsmpziwpn l0
18 Mar 19
Regulation FD Disclosure
6:38am
8-K
50mkejxzh8l
18 Mar 19
Regulation FD Disclosure
6:35am
8-K
54d4i5zck6av5en
13 Mar 19
Regulation FD Disclosure
12:00am